Navigation Links
Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
Date:8/7/2012

SAN DIEGO, Aug. 7, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the second quarter of 2012. For the three months ended June 30, 2012, Orexigen reported a net loss of $16.7 million, or $0.25 per share, as compared to a net loss of $7.6 million, or $0.16 per share, for the second quarter of 2011. As of June 30, 2012, Orexigen had $67.4 million in cash and cash equivalents and an additional $58.8 million in marketable securities, for a total of $126.2 million.

Total operating expenses for the second quarter of 2012 were $17.6 million compared to $8.3 million for the second quarter of 2011. This overall increase in operating expenses reflects an increase in research and development expenses associated with the conduct of the Light Study, the Contrave® cardiovascular outcomes trial.

"We are pleased to see that the coordinated effort of our team and our partners is resulting in terrific progress for the Light Study, which continues to rapidly enroll the targeted patient population," said Michael Narachi, president and CEO of Orexigen. "We remain focused on doing everything we can to pull forward the time to resubmission of the Contrave NDA."

"We are encouraged that the FDA has recently approved two weight loss drugs, and we congratulate our colleagues at Arena and Vivus on their recent success," Narachi continued. "With a pipeline of two late stage obesity therapeutics, this is clearly also good news for Orexigen."

Product candidate update:

  • Contrave® (32 mg naltrexone sustained-release (SR)/360 mg bupropion SR) for the treatment of obesity: In the second quarter, Orexigen initiated the Light Study which is designed to be conducted at approximately 300 sites in the United States. The primary ob
    '/>"/>

  • SOURCE Orexigen Therapeutics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
    2. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
    3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
    4. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
    5. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
    6. Cempra, Inc. to Present at the NIAID Workshop Bridging the Gap - Overcoming Bottlenecks in the Development of Therapeutics for Infectious Diseases
    7. Nile Therapeutics Promotes Darlene Horton, M.D., to Chief Executive Officer and Director
    8. Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019
    9. Silence Therapeutics - Admission of Shares and Board Update
    10. OrPro Therapeutics Receives NIH Grant Award to Advance Development of Recombinant Thioredoxin for Treatment of Cystic Fibrosis
    11. Cell Therapeutics Announces Institutional Investor Purchased Additional $15 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/19/2014)... 2014  RESMED INC. (NYSE: RMD ) today ... year 2015 results on Thursday, January 22, 2015, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
    (Date:12/19/2014)... 18, 2014   Aratana Therapeutics, Inc . ... focused on the licensing, development and commercialization of ... results from its pivotal field study of AT-001 ... in dogs with osteoarthritis.  In the study, dogs ... that were statistically significant compared to placebo (p<0.05) ...
    (Date:12/17/2014)... and SAN DIEGO , Dec. 17, 2014 ... ; AEX: PHIA) and Volcano Corporation (NASDAQ: VOLC ... for cardiovascular applications, today announced that they have entered into ... commence a tender offer to acquire all of the issued ... or a total equity purchase price of USD 1 billion ...
    Breaking Medicine Technology:ResMed To Announce Second Quarter 2015 Results 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8
    ... Spanish drug companies face a number of obstacles ...  From regulatory (FDA) and GMP compliance, to distribution agreements ... areas that must be coordinated.  Those issues have just ... U.S. company VPCI have entered into a joint association. ...
    ... Sherpa Clinical Packaging, a privately held provider of ... cutting ceremony today to mark the opening of ... San Diego, CA.  Sherpa,s employees and invited guests ... adjacent to the Althea Technologies campus in Sorrento ...
    Cached Medicine Technology:Spanish Drug Companies Have New Support Option for the U.S. Market 2Sherpa Clinical Packaging Completes New Production Facility 2
    (Date:12/20/2014)... MissyDress, a distinguished special dress supplier, ... The business has drastically cut prices to all its ... until Jan. 30, 2015. Many of the hottest styles ... dresses, lace dresses, and more. , A spokesman for ... day. Whether A-line princess prom dresses or sweetheart chiffon ...
    (Date:12/20/2014)... 2014 The print component of Healthy ... distribution of approximately 160,000 copies and an estimated readership ... a vast social media strategy and across a network ... the digital version of the campaign, click here ... with the ladies of CTV’s The Social. Lainey ...
    (Date:12/20/2014)... New York (PRWEB) December 20, 2014 ... continue to move forward in U.S. courts, Bernstein ... study which suggests that children treated with the ... hormone linked to breast development and lactation. The ... at 34 children and adolescents who began treatment ...
    (Date:12/20/2014)... Columbus, OH (PRWEB) December 20, 2014 ... contend they suffered uncontrollable bleeding and other ... District Court, Eastern District of Louisiana for coordinated pretrial ... Panel on Multidistrict Litigation (JPML) issued an order Friday ... tag-along actions pending in 22 federal courts to the ...
    (Date:12/19/2014)... It’s very easy to become overwhelmed with ... put to the wayside until Christmas and the New Year ... “itch” and that burning desire to just escape it all ... journey to Telluride with a no-fuss, affordable package. Montrose Days ... the resort, and ensure that all accommodations are met. Plus, ...
    Breaking Medicine News(10 mins):Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 3Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 4Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2
    ... Harris ... , ... 2009 -- Harris Williams & Co. is pleased to announce that Verathon Inc., a portfolio ... buyer Roper Industries (NYSE: ROP). Harris Williams & Co. acted as the exclusive advisor ...
    ... , HOLMDEL, ... Sparta Systems, Inc., the maker of TrackWise (®) software ... solutions, is pleased to announce new additions to the TrackWise ... Medical Device Vigilance reporting. The addition of ClinicalTrials.gov reporting ...
    ... , , , ... Quality Alliance (MTQUA, http://www.mtqua.org ), announces the first ... medical travel providers worldwide. , "All medical tourists who want ... medical travel with a Certified International Patient Advisor (CIPA) and ...
    ... 2010 AIUM Annual Convention and Preconvention Program, the only ... all disciplines of medical ultrasound, to be held March ... Convention focuses on emerging applications and unique opportunities for ... continues to advance and expand into new arenas. ...
    ... not being vaccinated against the seasonal flu any more often ... the importance of influenza vaccines resulting from the worldwide outbreak ... study. As of the middle of November, about 32 ... recommended to receive a flu vaccination had been inoculated against ...
    ... Finding is good news for first-line treatment in Africa, researchers ... finding that has implications for how the AIDS virus is ... be given without routine monitoring by lab tests. , But ... to monitor the progression of the disease and guide the ...
    Cached Medicine News:Health News:Harris Williams & Co. Advises Verathon Inc. in its Sale to Strategic Buyer Roper Industries 2Health News:Harris Williams & Co. Advises Verathon Inc. in its Sale to Strategic Buyer Roper Industries 3Health News:TrackWise(R) Electronic Regulatory Reporting Solution Enables Companies to Meet Current and Future Mandates 2Health News:TrackWise(R) Electronic Regulatory Reporting Solution Enables Companies to Meet Current and Future Mandates 3Health News:Medical Travel Quality Alliance to Certify Medical Tourism Agents for Safer, Quality Health Care for Traveling International Patients 2Health News:AIUM gears up for 2010 Annual Convention in San Diego, Calif. 2Health News:American adults receiving flu vaccine at about the same rate as in 2008, study finds 2Health News:American adults receiving flu vaccine at about the same rate as in 2008, study finds 3
    ... This compact system provides an ... preparation in the laboratory, satellite lab ... proven HEMA-TEK staining method with wedge-smear ... delivers complete standardization in a safe ...
    It is a cardio-pulmonary exercise testing device....
    ... has digitally-controlled drive system which eliminates ... can wear out. There are no ... and fewer drive belts - resulting ... It can carry weights up to ...
    ... systems feature our internationally-acclaimed algorithm that ... algorithm has a proven record for ... situations; and it's just one of ... recognized market leader in the stress ...
    Medicine Products: